Management of hyperleukocytosis in pediatric acute myeloid leukemia using immediate chemotherapy without leukapheresis: results from the NOPHO-DBH AML 2012 Protocol.

Fecha de publicación: 01/09/2024 Fecha Ahead of Print: 09/05/2024

Autores de IIS La Fe

• José María Fernández Navarro

  Autor

Participantes ajenos a IIS La Fe

• Zeller B
• Arad-Cohen N
• Cheuk D
• De Moerloose B
• Hasle H
• Jahnukainen K
• Juul-Dam KL
• Kaspers G
• Kovalova Z
• Jonsson OG
• Lausen B
• Munthe-Kaas M
• Nystrom UN
• Palle J
• Pasauliene R
• Pronk CJ
• Saks K
• Tierens A
• Abrahamsson J

Grupos

• Investigación Clínica y Traslacional en Cáncer

  

  Leader

  José Gómez Codina

Abstract

Hyperleukocytosis (HL) in pediatric acute myeloid leukemia (AML) is associated with severe complications and inferior outcome. We report results on HL patients included in the NOPHO-DBH AML 2012 study. We recommended immediate start of full dose chemotherapy (etoposide [ETO] monotherapy for 5 days as part of the first course), avoiding leukapheresis (LA) and prephase chemotherapy (PCT). Of 714 included patients, 122 (17.1%) had HL, and 111 were treated according to the recommendations with ETO upfront without preceding LA or PCT. The first dose was applied the same day as the AML diagnosis or the day after in 94%. ETO was administered via peripheral veins in 37% of patients without major complications. After initiation of ETO the remaining WBC on days 2-5 was 69%, 36%, 17% and 8% of the pre-treatment level. On day 3, 81% had a WBC.

Keywords

• ACUTE MYELOGENOUS LEUKEMIA; EARLY MORTALITY; THERAPEUTIC LEUKAPHERESIS; EXCHANGE-TRANSFUSION; EARLY COMPLICATIONS; SINGLE-CENTER; EARLY DEATH; CHILDREN; IMPACT; RISK